academic article

• A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results..  Journal of the American Academy of Dermatology.  85:379-387. 2021